VERIPURE
Live / Applied — First extension granted (statement of use) (as of 21 Oct 2025)
What this means for you
Not registered yet, but its 12 Oct 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97628473
- Mark type
- Stylized text
- Filed
- 12 Oct 2022
- Published for opposition
- 04 Mar 2025
- Attorney of record
- Daan G. Erikson
Goods and services
- Class 001 — Chemicals: Diagnostic reagents for in virology, microbiology and ophthalmology
- Class 005 — Pharmaceuticals: Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of tumors; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of solid tumors, namely, melanoma, breast cancer, basal cell carcinoma, prostate cancer, and small cell and non-small cell lung cancer, squamous cell carcinoma and primary and metastatic liver cancers; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of pediatric solid tumors, namely, Ewing sarcoma, neuroblastoma, osteosarcoma, neuroepithelioma, and rhabdomyosarcoma; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of leukemia; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of leukemia, namely, acute B-cell lymphoblastic leukemia, T-cell lymphoblastic leukemia, acute myeloid leukemia; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of psoriasis; Preparations for pharmaceutical skin care; Diagnostic preparations for medical use, namely, for use in virology, microbiology, ophthalmology; Diagnostic mediums for use in virology, microbiology, ophthalmology; Pharmaceutical preparations and substances for use as vaccine adjuvants, immune system stimulators or suppressors, and immune system modulators
Owner
- Provectus Pharmatech, Inc., Knoxville, TN, US
- Provectus Pharmatech, Inc., Knoxville, TN, US
Prosecution history
- 24 Jan 2026 — ASSIGNED TO EXAMINER
- 21 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Oct 2025 — SOU EXTENSION 1 GRANTED
- 21 Oct 2025 — SOU EXTENSION 1 FILED
- 21 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Mar 2025 — PUBLISHED FOR OPPOSITION
- 04 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Aug 2024 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 14 Feb 2024 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 17 Aug 2023 — CORRESPONDENCE E-MAILED
- 17 Aug 2023 — SUSPENSION LETTER WRITTEN
- 17 Aug 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED